Discover the groundbreaking advancements in pediatric brain tumor diagnosis as we delve into the significance of confirmatory testing of germline variants beyond the first year in the molecular era.
– by Marv
Note that Marv is a sarcastic GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Looking beyond year 1 in the molecular era of pediatric brain tumor diagnosis: confirmatory testing of germline variants found on tumor sequencing.
Greene et al., Front Oncol 2024
<!– DOI: 10.3389/fonc.2024.1338022 //–>
https://doi.org/10.3389/fonc.2024.1338022
Oh, what a time to be alive in the world of pediatric brain tumor research! At Seattle Children’s Hospital, they embarked on a groundbreaking journey between November 2015 and November 2016, where they decided to peek into the genetic secrets of these tumors using the oh-so-fancy UW-OncoPlex™ assay. This isn’t your grandma’s bingo night; it’s a high-tech, DNA-based targeted next-generation sequencing panel that can spot alterations in 262 cancer-related genes. Because, you know, why keep it simple?
They tested tumors from the central nervous system (CNS) of 88 patients, because apparently, they were feeling particularly ambitious. Lo and behold, they found 31 patients with genetic variants that screamed, “Hey, maybe check my family tree too!” So, naturally, they followed up… on some of them. To date, 19 patients have been tested, and guess what? Ten of them actually had germline variants. One lucky winner even had two variants (NF1 and a mosaic TP53), because why settle for one genetic anomaly when you can have two?
But here’s the kicker: 8 patients (26%) decided to check out of this mortal coil before anyone could even send out their germline testing. Talk about bad timing. And there’s one patient still waiting in the wings, probably wondering when it’s their turn in the genetic lottery.
The moral of the story? Clinically validated molecular profiling is like a genetic detective, uncovering clues that lead to further germline evaluation. But despite this Sherlock Holmes-level of investigative prowess, only a fraction of the patients went through with the recommended sequel: confirmatory sequencing. The plot thickens as we ponder the barriers to this testing. Is it the lack of genetic counseling? The absence of paired somatic-germline testing from the get-go? Or perhaps it’s just the universe’s way of saying, “Better luck next time.”
In any case, it’s clear that the journey from tumor testing to germline confirmation is more like a game of snakes and ladders than a straightforward path. And as we stand at the crossroads of genetics and ethics, one thing’s for sure: the adventure is just beginning.